Skip to content
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
<< Back
Aug 31, 2022

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

New data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris.

“The abstracts we’ll share at ESMO 2022 reinforce the value our genomic tests bring to physicians diagnosing and treating cancer patients,” said Marc Stapley, Veracyte’s chief executive officer. “We are particularly excited about new data from a post-hoc analysis that evaluated the clinical performance of our Decipher Prostate test in one arm of the large, multi-center, randomized STAMPEDE trial. We believe these data may help expand the Decipher test’s availability to advanced prostate cancer patients in the United States, and also support our plans to offer the Decipher Prostate test as an IVD on the nCounter Analysis System for use outside of the United States where laboratories can perform it locally.”

Following are details of the abstracts that will be shared as part of the ESMO 2022 Congress:

Title:

Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): an ancillary study of the STAMPEDE AAP trial

Presenter:

Marina Perry, PhD, University College London Cancer Institute

Date/Time:

September 11, 2022, 8:40-8:50 a.m. CEST

Presentation #:

1358O

 

 

Title:

A Transcriptomic Signature of AR Activity Prognosticates Development of Castration-Resistance following Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

Presenter:

Phuoc Tran, MD, PhD, University of Maryland School of Medicine

Date/Time:

September 11, 2022

Poster #:

1381P

 

 

Title:

Transcriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer

Presenter:

Edward M. Schaeffer, MD, PhD, Northwestern Medicine

Date/Time:

September 11, 2022

Poster #:

1377P

 

 

Title:

Biopsy-based Basal-Luminal Subtyping Classifier in High-risk Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials

Presenter:

Paul Nguyen, MD, Brigham and Women’s Hospital

Date/Time:

September 11, 2022

Poster #:

1378P

 

 

Title:

Transcriptomic-based prognostic and predictive biomarker analysis of ENACT: a randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)

Presenter:

Ashley Ross, MD, PhD, Feinberg School of Medicine at Northwestern University

Date/Time:

September 11, 2022

Poster #:

1385P

 

 

Title:

Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa)

Presenter:

M.L.K. Chua, MD, PhD, National Cancer Centre Singapore

Date/Time:

September 11, 2022

Poster #:

1408P

 

 

Title:

Current use of breast cancer multigene signatures in clinical practice among European experts: results from the PROCURE Project

Presenter:

Giuseppe Curigliano, MD, PhD, IEO - Istituto Europeo di Oncologia

Date/Time:

September 11, 2022

Poster #:

164P

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. An example of a forward-looking statement includes, among others, that data presented at the ESMO Congress may help expand availability of our Decipher Prostate Genomic Classifier.

Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q to be filed for the three months ended June 30, 2022. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, Decipher and Prosigna are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.

Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.

Investors:
Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
Vice President of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.